These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15529488)

  • 1. Drug-eluting stents are here--now what? Implications for clinical practice and health care costs.
    Hirshfeld JW; Wilensky RL
    Cleve Clin J Med; 2004 Oct; 71(10):825-8. PubMed ID: 15529488
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-eluting stents: costs versus clinical benefit.
    O'Neill WW; Leon MB
    Circulation; 2003 Jun; 107(24):3008-11. PubMed ID: 12821587
    [No Abstract]   [Full Text] [Related]  

  • 3. Economics of sirolimus-eluting stents: drug-eluting stents have really arrived.
    Weintraub WS
    Circulation; 2004 Aug; 110(5):472-4. PubMed ID: 15289386
    [No Abstract]   [Full Text] [Related]  

  • 4. Examining the economic impact of restenosis: implications for the cost-effectiveness of an antiproliferative stent.
    Greenberg D; Cohen DJ
    Z Kardiol; 2002; 91 Suppl 3():137-43. PubMed ID: 12641029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
    Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
    Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.
    Zbinden R; von Felten S; Wein B; Tueller D; Kurz DJ; Reho I; Galatius S; Alber H; Conen D; Pfisterer M; Kaiser C; Eberli FR
    Cardiovasc Ther; 2017 Feb; 35(1):19-25. PubMed ID: 27662632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The costs and quality-of-life outcomes of drug-eluting coronary stents: a systematic review.
    Groeneveld PW; Suh JJ; Matta MA
    J Interv Cardiol; 2007 Feb; 20(1):1-9. PubMed ID: 17300390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-eluting versus bare-metal coronary stents: where are we now?
    Amoroso NS; Bangalore S
    J Comp Eff Res; 2012 Nov; 1(6):501-8. PubMed ID: 24236469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting stents versus bare metal stents.
    Conti CR
    Clin Cardiol; 2003 Nov; 26(11):493-4. PubMed ID: 14640461
    [No Abstract]   [Full Text] [Related]  

  • 10. New technologies in percutaneous coronary interventions: drug-coated balloons.
    Kleber FX; Scheller B; Serruys PW
    EuroIntervention; 2011 May; 7 Suppl K():K7. PubMed ID: 22027732
    [No Abstract]   [Full Text] [Related]  

  • 11. NICE guidelines for the use of drug-eluting stents: how do we establish worth?
    de Belder MA;
    Heart; 2008 Dec; 94(12):1646-8. PubMed ID: 18728067
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil.
    Polanczyk CA; Wainstein MV; Ribeiro JP
    Arq Bras Cardiol; 2007 Apr; 88(4):464-74. PubMed ID: 17546279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we afford to eliminate restenosis? Can we afford not to?
    Greenberg D; Bakhai A; Cohen DJ
    J Am Coll Cardiol; 2004 Feb; 43(4):513-8. PubMed ID: 14975456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary on drug-eluting stents: to use or not to use--that is the question!
    Pfisterer ME
    Heart; 2008 Dec; 94(12):1648-50. PubMed ID: 18782796
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug-eluting stents: the beginning of the end of restenosis?
    Haery C; Sachar R; Ellis SG
    Cleve Clin J Med; 2004 Oct; 71(10):815-24. PubMed ID: 15529487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary on drug-eluting stents: NICE technology appraisal guidance.
    Richardson J; Stevens A; Barnett D; Longson C
    Heart; 2008 Dec; 94(12):1650-2. PubMed ID: 18768567
    [No Abstract]   [Full Text] [Related]  

  • 17. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
    Kastrati A; Mehilli J; von Beckerath N; Dibra A; Hausleiter J; Pache J; Schühlen H; Schmitt C; Dirschinger J; Schömig A;
    JAMA; 2005 Jan; 293(2):165-71. PubMed ID: 15644543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decision models for assessing the cost effectiveness of drug-eluting stents.
    Kong DF; Eisenstein EL
    Expert Opin Pharmacother; 2005 Jun; 6(6):965-74. PubMed ID: 15952924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting stents substantially lower rate of restenosis.
    Rollins G
    Rep Med Guidel Outcomes Res; 2003 Oct; 14(20):7-9. PubMed ID: 14584494
    [No Abstract]   [Full Text] [Related]  

  • 20. Meta-analysis of randomized trials comparing the effectiveness of different strategies for the treatment of drug-eluting stent restenosis.
    Piccolo R; Galasso G; Piscione F; Esposito G; Trimarco B; Dangas GD; Mehran R
    Am J Cardiol; 2014 Nov; 114(9):1339-46. PubMed ID: 25242363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.